Damora Therapeutics (DMRA) Change in Accured Expenses (2019 - 2026)
Damora Therapeutics (DMRA) posted Change in Accured Expenses of $3.6 million for Q1 2026, up 2076.37% on a QoQ basis from -$182000.0 in Q4 2025, and up 854.11% year-over-year from $377000.0 in Q1 2025.
Damora Therapeutics (DMRA) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Damora Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 854.11% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 428.94% YoY) and the FY2025 annual result came in at $1.1 million, up 135.01% from the prior year.
- Change in Accured Expenses was $3.6 million for Q1 2026 at Damora Therapeutics, up from -$182000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q1 2026 and bottomed at -$3.8 million in Q4 2023.
- A 5-year average of $169882.4 and a median of $377000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 606.02% — and 2026, when it soared 854.11%.
- Damora Therapeutics' Change in Accured Expenses stood at $747000.0 in 2022, then tumbled by 606.02% to -$3.8 million in 2023, then soared by 70.93% to -$1.1 million in 2024, then surged by 83.44% to -$182000.0 in 2025, then jumped by 2076.37% to $3.6 million in 2026.
- Business Quant data shows DMRA's Change in Accured Expenses at $3.6 million in Q1 2026, -$182000.0 in Q4 2025, and $230000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.60 Mn |
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | -182,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Jun 30, 2025 | 674,000.00 |
| Jun 30, 2025 | 674,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Dec 31, 2024 | -1.10 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | 411,000.00 |
| Jun 30, 2024 | 411,000.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Dec 31, 2023 | -3.78 Mn |